الفهرس 
COVEROnly 14 pages are availabe for public view
 |  | from | 149 |  |  |
| | | from | 149 | | |
Abstract
With Cancer representing a global health problem, causing over 13% of the deaths worldwide and with the lack of a safe, effective and convenient therapy, the search for new
targeted effective agents to combat cancer is becoming an urgent need. Understanding cancer causes and detailed study of its treatments has enabled the identification of
potential drug targets, one of the most promising of which is the of human epidermal growth factor receptor (HER2) and epidermal growth factor receptor (EGFR); In addition,
several EGFR and HER2 inhibitors have proven success in clinical trials against several types of cancers. This encouraged us to select both EGFR and HER2 as targets for this study. In this investigation, we designed and synthesized anilinoquinazoline derivatives
bearing bulky arylpyridinyl IV& V, arylpropenoyl VI and arylpyrazolyl VII moieties at the4’ position of the anilinoquinazoline, as HER2/EGFR dual kinase inhibitors, capable offitting into the receptor ATP binding sites. This was further supported by molecularmodelling studies performed on Schrödinger Software through docking of thesecompounds in the EGFR and HER2 ATP binding site to assess their binding modes andbinding affinities. Synthesis of the designed compounds was then accomplished & theirstructures were confirmed by various spectral and micro-analytical data. The study involved the synthesis of the following unavailable reported intermediates:
1. Quinazolin-4(3H)-one(Ia)
2. 6,7-Dimethoxy-quinazolin-4(3H)-one(Ib)
3. 4-Chloroquinazoline(IIa)
4. 4-Chloro-6,7-dimethoxy-3,4-dihydroquinazoline(IIb)
5. 4-(4-Acetyphenylamino)quinazoline (IIIa)
6. 4-(4-Acetylphenylamino)-6,7-dimethoxyquinazoline (IIIb)